LABELS · 7c9667b2-3981-4256-a6a5-0c862549f837

Docetaxel

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2024-12-06
Captured: 2026-09-09T23:37:51.659493+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION Treatment-related mortality associated with Docetaxel therapy is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive Docetaxel as a single agent at a dose of 100 mg/m 2 [see Warnings and Precautions (5.1) ] . Avoid the use of Docetaxel in patients with bilirubin > upper limit of normal (ULN), or to patients with AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN. Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase >1.5 × ULN also had a higher rate of febrile neutropenia. Measure bilirubin, AST or ALT, and alkaline phosphatase prior to each cycle of Docetaxel [see Warnings and Precautions (5.2) ] . Do not administer Docetaxel to patients with neutrophil counts of <1500 cells/mm 3 . Monitor blood counts frequently as neutropenia may be severe and result in infection [see Warnings and Precautions (5.3) ] . Do not administer Docetaxel to patients who have a history of severe hypersensitivity reactions to Docetaxel or to other drugs formulated with polysorbate 80 [see Contraindications (4) ] . Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the Docetaxel infusion and administration of appropriate therapy [see Warnings and Precautions (5.5) ] . Severe fluid retention occurred in 6.5% (6/92) of patients despite use of dexamethasone premedication. It was characterized by one or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites) [see Warnings and Precautions (5.6) ] . WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION See full prescribing information for complete boxed warning. Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based therapy receiving Docetaxel at 100 mg/m 2 ( 5.1 ) Avoid use of Docetaxel if bilirubin > ULN, or if AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN. LFT elevations increase risk of severe or life-threatening complications. Obtain LFTs before each treatment cycle ( 5.2 ) Do not administer Docetaxel to patients with neutrophil counts <1500 cells/mm 3 . Obtain frequent blood counts to monitor for neutropenia ( 4 , 5.3 ) Severe hypersensitivity, including fatal anaphylaxis, has been reported in patients who received dexamethasone premedication. Severe reactions require immediate discontinuation of docetaxel and administration of appropriate therapy ( 5.5 ) Contraindicated if history of severe hypersensitivity reactions to Docetaxel or to drugs formulated with polysorbate 80 ( 4 ) Severe fluid retention may occur despite dexamethasone ( 5.6 )

Indications and usage: exact source text

1 INDICATIONS AND USAGE Docetaxel is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN) : with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Full extracted label fields

application numbers

NDA020449

boxed warning exact

WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION Treatment-related mortality associated with Docetaxel therapy is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive Docetaxel as a single agent at a dose of 100 mg/m 2 [see Warnings and Precautions (5.1) ] . Avoid the use of Docetaxel in patients with bilirubin > upper limit of normal (ULN), or to patients with AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN. Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase >1.5 × ULN also had a higher rate of febrile neutropenia. Measure bilirubin, AST or ALT, and alkaline phosphatase prior to each cycle of Docetaxel [see Warnings and Precautions (5.2) ] . Do not administer Docetaxel to patients with neutrophil counts of <1500 cells/mm 3 . Monitor blood counts frequently as neutropenia may be severe and result in infection [see Warnings and Precautions (5.3) ] . Do not administer Docetaxel to patients who have a history of severe hypersensitivity reactions to Docetaxel or to other drugs formulated with polysorbate 80 [see Contraindications (4) ] . Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the Docetaxel infusion and administration of appropriate therapy [see Warnings and Precautions (5.5) ] . Severe fluid retention occurred in 6.5% (6/92) of patients despite use of dexamethasone premedication. It was characterized by one or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites) [see Warnings and Precautions (5.6) ] . WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION See full prescribing information for complete boxed warning. Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based therapy receiving Docetaxel at 100 mg/m 2 ( 5.1 ) Avoid use of Docetaxel if bilirubin > ULN, or if AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN. LFT elevations increase risk of severe or life-threatening complications. Obtain LFTs before each treatment cycle ( 5.2 ) Do not administer Docetaxel to patients with neutrophil counts <1500 cells/mm 3 . Obtain frequent blood counts to monitor for neutropenia ( 4 , 5.3 ) Severe hypersensitivity, including fatal anaphylaxis, has been reported in patients who received dexamethasone premedication. Severe reactions require immediate discontinuation of docetaxel and administration of appropriate therapy ( 5.5 ) Contraindicated if history of severe hypersensitivity reactions to Docetaxel or to drugs formulated with polysorbate 80 ( 4 ) Severe fluid retention may occur despite dexamethasone ( 5.6 )

brand names

Docetaxel

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52

generic names

DOCETAXEL

7c9667b2-3981-4256-a6a5-0c862549f837

indications and usage exact

1 INDICATIONS AND USAGE Docetaxel is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN) : with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

indications and usage tables exact

is original packager

true

manufacturer names

Sanofi-Aventis U.S. LLC

matched search terms

cancer
carcinoma

package ndcs

0955-1021-04
0955-1020-01
0955-1022-08

product ndcs

0955-1020
0955-1021
0955-1022

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRAVENOUS

rxcuis

1860480
1860485
1861411

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00400.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA020449

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1095
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Docetaxel is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN) : with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel in combination with doxorubicin
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 0

current approval status

not_reconciled

duplicate text group

dup-adbae5b78bca60a5190f

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-617e43116a1148a8b6ac

label id

7c9667b2-3981-4256-a6a5-0c862549f837

positive predicate support span

end: 70
end exclusive: true
exact text: is a microtubule inhibitor indicated
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 34

qualifier mentions

context exact
: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant trea
kind
biomarker
polarity
not_inferred
span
end
174
end exclusive
true
exact text
metastatic BC after chemotherapy failure
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
134
context exact
Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced
kind
biomarker
polarity
not_inferred
span
end
394
end exclusive
true
exact text
metastatic NSCLC after platinum therapy fai
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
351
context exact
e; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC) : with pred
kind
biomarker
polarity
not_inferred
span
end
487
end exclusive
true
exact text
metastatic untreated NSCLC ( 1
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
457
context exact
ation-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC) : with cisplatin an
kind
biomarker
polarity
not_inferred
span
end
600
end exclusive
true
exact text
metastatic castration-resistant prostate ca
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
557
context exact
ibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adju
kind
stage_or_setting
polarity
not_inferred
span
end
165
end exclusive
true
exact text
locally advanced or metastatic BC after chemotherap
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
114
context exact
erapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC) : single age
kind
stage_or_setting
polarity
not_inferred
span
end
264
end exclusive
true
exact text
adjuvant treatment of operable node-positiv
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
221
context exact
1.1 ) Non-small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, local
kind
stage_or_setting
polarity
not_inferred
span
end
382
end exclusive
true
exact text
locally advanced or metastatic NSCLC after platinum
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
331
context exact
SCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Cas
kind
stage_or_setting
polarity
not_inferred
span
end
435
end exclusive
true
exact text
unresectable
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
423
context exact
tinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC) : with pred
kind
stage_or_setting
polarity
not_inferred
span
end
487
end exclusive
true
exact text
locally advanced or metastatic untreated NSCLC ( 1
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
437
context exact
ation-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC) : with cisplatin and
kind
stage_or_setting
polarity
not_inferred
span
end
602
end exclusive
true
exact text
metastatic castration-resistant prostate canc
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
557
context exact
inoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous C
kind
stage_or_setting
polarity
not_inferred
span
end
701
end exclusive
true
exact text
advanced GC
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
690
context exact
with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 )
kind
stage_or_setting
polarity
not_inferred
span
end
891
end exclusive
true
exact text
locally advanced SCCHN ( 1
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
865

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
311
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
277

source span

end: 895
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Docetaxel is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN) : with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 )
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%227c9667b2-3981-4256-a6a5-0c862549f837%22

spl effective date

2024-12-06

spl set id

dd0ca36d-1f54-4568-8d19-a7152addcd52

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · positive indication candidate

application numbers

NDA020449

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1253
end exclusive: true
exact text: ed GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN) : with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 696

current approval status

not_reconciled

duplicate text group

dup-94857eb356471aa854d6

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-83e1be47a6ef939546c9

label id

7c9667b2-3981-4256-a6a5-0c862549f837

positive predicate support span

end: 936
end exclusive: true
exact text: is indicated
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 924

qualifier mentions

context exact
ated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
kind
biomarker
polarity
not_inferred
span
end
1035
end exclusive
true
exact text
metastatic breast cancer after failure of p
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
992
context exact
r Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
kind
stage_or_setting
polarity
not_inferred
span
end
1023
end exclusive
true
exact text
locally advanced or metastatic breast cancer after
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
972

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
311
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
277

source span

end: 1053
end exclusive: true
exact text: 1.1 Breast Cancer Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 896

source url

https://api.fda.gov/drug/label.json?search=id%3A%227c9667b2-3981-4256-a6a5-0c862549f837%22

spl effective date

2024-12-06

spl set id

dd0ca36d-1f54-4568-8d19-a7152addcd52

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 3 · positive indication candidate

application numbers

NDA020449

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1411
end exclusive: true
exact text: eatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-ba
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 854

current approval status

not_reconciled

duplicate text group

dup-b2e1ea9c2d81f1b0aa35

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-88218f619795e61ff7ef

label id

7c9667b2-3981-4256-a6a5-0c862549f837

positive predicate support span

end: 1129
end exclusive: true
exact text: is indicated
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 1117

qualifier mentions

context exact
with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
kind
stage_or_setting
polarity
not_inferred
span
end
1181
end exclusive
true
exact text
adjuvant treatment of patients with operabl
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
1138
context exact
Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
kind
regimen
polarity
not_inferred
span
end
1210
end exclusive
true
exact text
in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
1064

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
311
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
277

source span

end: 1211
end exclusive: true
exact text: Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 1054

source url

https://api.fda.gov/drug/label.json?search=id%3A%227c9667b2-3981-4256-a6a5-0c862549f837%22

spl effective date

2024-12-06

spl set id

dd0ca36d-1f54-4568-8d19-a7152addcd52

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 4 · positive indication candidate

application numbers

NDA020449

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1628
end exclusive: true
exact text: ncer after failure of prior chemotherapy. Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemot
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 1012

current approval status

not_reconciled

duplicate text group

dup-17c962fc60a3057f0e92

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-bb5fd1f7f614bfd404dd

label id

7c9667b2-3981-4256-a6a5-0c862549f837

positive predicate support span

end: 1283
end exclusive: true
exact text: is indicated
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 1271

qualifier mentions

context exact
ated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
kind
biomarker
polarity
not_inferred
span
end
1382
end exclusive
true
exact text
metastatic non-small cell lung cancer after
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
1339
context exact
ingle agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
kind
stage_or_setting
polarity
not_inferred
span
end
1370
end exclusive
true
exact text
locally advanced or metastatic non-small cell lung
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
1319
context exact
1.2 Non-small Cell Lung Cancer Docetaxel as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
kind
regimen
polarity
not_inferred
span
end
1427
end exclusive
true
exact text
as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
1253

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
311
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
277

source span

end: 1428
end exclusive: true
exact text: 1.2 Non-small Cell Lung Cancer Docetaxel as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 1212

source url

https://api.fda.gov/drug/label.json?search=id%3A%227c9667b2-3981-4256-a6a5-0c862549f837%22

spl effective date

2024-12-06

spl set id

dd0ca36d-1f54-4568-8d19-a7152addcd52

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 5 · positive indication candidate

application numbers

NDA020449

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1854
end exclusive: true
exact text: l Lung Cancer Docetaxel as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel in c
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 1229

current approval status

not_reconciled

duplicate text group

dup-4bf571f735cd848b894f

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-cfdc8b8765b6a22fda8d

label id

7c9667b2-3981-4256-a6a5-0c862549f837

positive predicate support span

end: 1481
end exclusive: true
exact text: is indicated
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 1469

qualifier mentions

context exact
reatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.
kind
biomarker
polarity
not_inferred
span
end
1594
end exclusive
true
exact text
metastatic non-small cell lung cancer who h
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
1551
context exact
h cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer
kind
stage_or_setting
polarity
not_inferred
span
end
1529
end exclusive
true
exact text
unresectable
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
1517
context exact
indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for thi
kind
stage_or_setting
polarity
not_inferred
span
end
1582
end exclusive
true
exact text
locally advanced or metastatic non-small cell lung
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
1531
context exact
Docetaxel in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.
kind
regimen
polarity
not_inferred
span
end
1618
end exclusive
true
exact text
in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously recei
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
1439

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
311
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
277

source span

end: 1654
end exclusive: true
exact text: Docetaxel in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 1429

source url

https://api.fda.gov/drug/label.json?search=id%3A%227c9667b2-3981-4256-a6a5-0c862549f837%22

spl effective date

2024-12-06

spl set id

dd0ca36d-1f54-4568-8d19-a7152addcd52

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 6 · positive indication candidate

application numbers

NDA020449

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2012
end exclusive: true
exact text: ith cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the ga
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 1455

current approval status

not_reconciled

duplicate text group

dup-0952fdf9ccdc80242706

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-4555d6e202ed40336741

label id

7c9667b2-3981-4256-a6a5-0c862549f837

positive predicate support span

end: 1728
end exclusive: true
exact text: is indicated
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 1716

qualifier mentions

context exact
prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
kind
biomarker
polarity
not_inferred
span
end
1807
end exclusive
true
exact text
metastatic castration-resistant prostate ca
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
1764
context exact
prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
kind
stage_or_setting
polarity
not_inferred
span
end
1809
end exclusive
true
exact text
metastatic castration-resistant prostate canc
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
1764
context exact
1.3 Prostate Cancer Docetaxel in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
kind
regimen
polarity
not_inferred
span
end
1811
end exclusive
true
exact text
in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
1685

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
311
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
277

source span

end: 1812
end exclusive: true
exact text: 1.3 Prostate Cancer Docetaxel in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 1655

source url

https://api.fda.gov/drug/label.json?search=id%3A%227c9667b2-3981-4256-a6a5-0c862549f837%22

spl effective date

2024-12-06

spl set id

dd0ca36d-1f54-4568-8d19-a7152addcd52

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 7 · positive indication candidate

application numbers

NDA020449

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2299
end exclusive: true
exact text: received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and ne
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 1613

current approval status

not_reconciled

duplicate text group

dup-8d40687da2c20ab5a261

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-302104428d8e5f53730e

label id

7c9667b2-3981-4256-a6a5-0c862549f837

positive predicate support span

end: 1909
end exclusive: true
exact text: is indicated
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 1897

qualifier mentions

context exact
luorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction,
kind
stage_or_setting
polarity
not_inferred
span
end
1976
end exclusive
true
exact text
advanced gastric adenocarcinoma
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
1945
context exact
geal junction, who have not received prior chemotherapy for advanced disease.
kind
stage_or_setting
polarity
not_inferred
span
end
2098
end exclusive
true
exact text
advanced disease
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
2082
context exact
1.4 Gastric Adenocarcinoma Docetaxel in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advance
kind
regimen
polarity
not_inferred
span
end
2029
end exclusive
true
exact text
in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal ju
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
1850

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
311
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
277

source span

end: 2099
end exclusive: true
exact text: 1.4 Gastric Adenocarcinoma Docetaxel in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease.
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 1813

source url

https://api.fda.gov/drug/label.json?search=id%3A%227c9667b2-3981-4256-a6a5-0c862549f837%22

spl effective date

2024-12-06

spl set id

dd0ca36d-1f54-4568-8d19-a7152addcd52

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 8 · positive indication candidate

application numbers

NDA020449

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2310
end exclusive: true
exact text: indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 1900

current approval status

not_reconciled

duplicate text group

dup-630b4e203a2733e318e9

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL

ind-span-c7bbc9314302392ff3a0

label id

7c9667b2-3981-4256-a6a5-0c862549f837

positive predicate support span

end: 2194
end exclusive: true
exact text: is indicated
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 2182

qualifier mentions

context exact
l is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
kind
stage_or_setting
polarity
not_inferred
span
end
2291
end exclusive
true
exact text
locally advanced squamous cell carcinoma of the hea
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
2240
context exact
1.5 Head and Neck Cancer Docetaxel in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
kind
regimen
polarity
not_inferred
span
end
2309
end exclusive
true
exact text
in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
2135

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
311
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
7c9667b2-3981-4256-a6a5-0c862549f837
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start
277

source span

end: 2310
end exclusive: true
exact text: 1.5 Head and Neck Cancer Docetaxel in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
label id: 7c9667b2-3981-4256-a6a5-0c862549f837
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: e732908a554889ce240c496907c7e49f2454ecf8172a85c6598a6a7b2a27ebda
start: 2100

source url

https://api.fda.gov/drug/label.json?search=id%3A%227c9667b2-3981-4256-a6a5-0c862549f837%22

spl effective date

2024-12-06

spl set id

dd0ca36d-1f54-4568-8d19-a7152addcd52

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Preserved source evidence · Not medical advice